JP2013544244A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544244A5
JP2013544244A5 JP2013539093A JP2013539093A JP2013544244A5 JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5 JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013539093 A JP2013539093 A JP 2013539093A JP 2013544244 A5 JP2013544244 A5 JP 2013544244A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
interleukin
inflammation
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013539093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544244A (ja
Filing date
Publication date
Priority claimed from CN201010551433.8A external-priority patent/CN102462837B/zh
Application filed filed Critical
Publication of JP2013544244A publication Critical patent/JP2013544244A/ja
Publication of JP2013544244A5 publication Critical patent/JP2013544244A5/ja
Pending legal-status Critical Current

Links

JP2013539093A 2010-11-19 2011-11-09 抗炎症組成物 Pending JP2013544244A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010551433.8A CN102462837B (zh) 2010-11-19 2010-11-19 抗炎组合物
CN201010551433.8 2010-11-19
PCT/AU2011/001446 WO2012065212A1 (en) 2010-11-19 2011-11-09 Anti-inflammatory compositions

Publications (2)

Publication Number Publication Date
JP2013544244A JP2013544244A (ja) 2013-12-12
JP2013544244A5 true JP2013544244A5 (enExample) 2014-12-25

Family

ID=46067145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539093A Pending JP2013544244A (ja) 2010-11-19 2011-11-09 抗炎症組成物

Country Status (12)

Country Link
US (1) US9289493B2 (enExample)
EP (1) EP2640411B1 (enExample)
JP (1) JP2013544244A (enExample)
KR (1) KR101989201B1 (enExample)
CN (1) CN102462837B (enExample)
AU (1) AU2011331901B2 (enExample)
CA (1) CA2817996C (enExample)
DK (1) DK2640411T3 (enExample)
MX (1) MX348794B (enExample)
MY (1) MY174797A (enExample)
RU (1) RU2627451C9 (enExample)
WO (1) WO2012065212A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811624T3 (es) 2011-03-11 2021-03-12 Hopitaux Paris Assist Publique Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
EP2683395B2 (en) * 2011-03-11 2026-05-20 Hopitaux Paris Assist Publique USE OF LOW-DOSE IL-2 FOR THE TREATMENT OF TYPE 1 DIABETIC DISORDERS
NL2009794C2 (nl) 2012-11-13 2014-05-14 Hevorma B V Groei-inrichting voor gewas, gebruik van een dergelijke inrichting, en een reeks groei-inrichtingen.
SI3482766T1 (sl) 2014-08-11 2020-09-30 Delinia, Inc. Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
KR20240167709A (ko) * 2015-02-25 2024-11-27 아웃센스 다이아그나스틱스 엘티디. 신체 배출물 분석
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
CN109963559A (zh) * 2016-09-15 2019-07-02 皮肤科技生命科学有限公司 舌下或颊部施用dim以治疗皮肤病
SG11201903882VA (en) 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
IL295826B2 (en) 2020-03-31 2025-11-01 Hanmi Pharmaceutical Co Ltd Novel immunostimulating il-2 analogs
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988001213A1 (en) * 1986-08-18 1988-02-25 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents
DK0462305T3 (da) * 1990-06-21 1995-04-24 Huland Edith Anvendelse af cytokinholdige aerosoler såvel som cytokholdige aerosoler i sig selv
US6509313B1 (en) * 1996-02-28 2003-01-21 Cornell Research Foundation, Inc. Stimulation of immune response with low doses of cytokines
US7361331B2 (en) * 1996-10-18 2008-04-22 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Agriculture And Agri-Food Plant bioreactors
JP4023863B2 (ja) 1997-03-13 2007-12-19 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Il−6を含む血清尿酸値低下剤
FR2769505B1 (fr) 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6685931B1 (en) * 1998-12-22 2004-02-03 Schering Corporation Treatment of hepatitis C virus infections with interleukin-10
DE60038304T3 (de) 1999-09-09 2017-04-06 Merck Sharp & Dohme Corp. Interleukin-12 p40 und interleukin-b30. kombinationen davon. antikörper. verwendungen in pharmazeutische zusammensetzungen
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
CN1688293A (zh) 2002-09-16 2005-10-26 韦思公司 多肽治疗剂口服给药的缓释配方及其使用方法
GB0501540D0 (en) * 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
CN101861162A (zh) 2007-03-14 2010-10-13 高世英 通过粘膜给予白介素治疗癌症的方法
CN102174111B (zh) * 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 人白介素2-Fc融合蛋白及其用途

Similar Documents

Publication Publication Date Title
RU2013127793A (ru) Противовоспалительные композиции
Jacques et al. The role of IL‐1 and IL‐1Ra in joint inflammation and cartilage degradation
AU2012229443B2 (en) Methods and compositions for treating hyperuricemia and metabolic disorders associated with hyperuricemia
JP2016523862A5 (enExample)
EP2011487A3 (en) Pharmaceutical compositions for gastroinetestinal drug delivery
JP2014526503A5 (enExample)
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
JP2013510123A5 (enExample)
JP2016517888A5 (enExample)
Lee et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial
JP2020514282A5 (enExample)
AR095372A1 (es) Terapia de inducción con rituximab seguida por una terapia con acetato de glatiramer
JP2018505158A5 (enExample)
JP2014523906A5 (enExample)
MX2012001196A (es) Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos.
JP2009544690A5 (enExample)
JP2019527714A5 (enExample)
MA38169B2 (fr) Ciclésonide pour le traitement d'une maladie des voies respiratoires chez les chevaux
JP2010500284A5 (enExample)
JP2005512946A5 (enExample)
JP2008516909A5 (enExample)
JP2012530755A5 (enExample)
RU2014125519A (ru) Ацил-гидразоновые и оксадиазоловые соединения, фармацевтические композиции, содержащие их, и их применение
JP2008533079A5 (enExample)
CN105147703B (zh) 黄柏酮在制备防治溃疡性结肠炎的药物中的应用